Antigens Patents (Class 435/69.3)
  • IMMUNOTHERAPY AND DIAGNOSIS OF MUCORMYCOSIS USING CotH
    Publication number: 20130108642
    Abstract: The invention provided Mucorales CotH polypeptides and encoding nucleic acid molecules. The Mucorales CotH polypeptides and encoding nucleic acids can be advantageously used to diagnose, treat or prevent fungal conditions, in particular mucormycosis.
    Type: Application
    Filed: September 14, 2012
    Publication date: May 2, 2013
    Inventors: Ashraf S. Ibrahim, Mingfu Liu, Teklegiorgis Ghebremariam, Yue Fu, John E. Edwards, Scott Filler
  • Methods for producing fusion polypeptides or enhancing expression of fusion polypeptides
    Patent number: 8426167
    Abstract: The present invention relates to the cloning and expression of foreign protein or polypeptides in bacteria, such as Escherichia coli. In particular, this invention relates to expression tools comprising a FKBP-type peptidyl prolyl isomerase selected from the group consisting of FkpA, SlyD, and trigger factor; methods of recombinant protein expression, the recombinant polypeptides thus obtained, as well as to the use of such polypeptides.
    Type: Grant
    Filed: April 13, 2007
    Date of Patent: April 23, 2013
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Christian Scholz, Herbert Andres, Elke Faatz, Alfred Engel, Urban Schmitt, Ariuna Bazarsuren, Peter Schaarschmidt
  • Method of Supplementing Culture Media to Prevent Undesirable Amino Acid Substitutions
    Publication number: 20130096283
    Abstract: The present invention relates to methods of reducing substitution of amino acids during the production of polypeptides of interest in mammalian cells. By varying the concentration of amino acids in the culture medium, heterogeneity of the polypeptide's amino acid sequence is decreased, leading to higher yields of functional protein.
    Type: Application
    Filed: November 24, 2009
    Publication date: April 18, 2013
    Applicant: Biogen Idec MA inc.
    Inventors: Anurag Khetan, Yao-ming Huang, Jana Dolnikova, Nels Pederson, Helena Yusuf-Makagiansar, Paul Chen, Thomas Ryll
  • Identification of antigens for use in the diagnosis, treatment, and monitoring of periodontal diseases
    Patent number: 8420340
    Abstract: Antibodies, polypeptides, and polynucleotides are provided for the detection, prevention, amelioration and treatment of diseases caused by Actinobacillus actinomycetemcomitans.
    Type: Grant
    Filed: May 20, 2011
    Date of Patent: April 16, 2013
    Assignee: University of Florida Research Foundation
    Inventors: Martin Handfield, Jeffrey Daniel Hillman, Ann Progulske-Fox
  • mutants and methods of use thereof
    Patent number: 8414903
    Abstract: The present invention provides methods and compositions for production of gram-negative bacterial mutants that are defective in intestinal colonization capacity and sensitive to infection by bacteriophage P1. Thus the present invention provides immunogenic compositions for the prevention or attenuation of food- and water-borne illnesses associated with ingestion of bacteria such as enterohemorrhagic Escherichia coli.
    Type: Grant
    Filed: November 20, 2007
    Date of Patent: April 9, 2013
    Assignee: Tufts University
    Inventors: Matthew K. Waldor, Theresa D. Ho
  • Nucleic acids encoding GAS57 mutant antigens
    Patent number: 8399651
    Abstract: The invention provides mutants of GAS57 (Spy0416) which are unable to cleave IL-8 and similar substrates but which still maintain the ability to induce protection against S. pyogenes. The invention also provides antibodies which specifically bind to GAS57 and which inhibit its ability to cleave IL-8 and similar substrates. The mutants are useful, inter alia, in vaccine compositions to induce protection against S. pyogenes. The antibodies are useful, e.g., as therapeutics for treating S. pyogenes infections.
    Type: Grant
    Filed: September 10, 2012
    Date of Patent: March 19, 2013
    Assignee: Novartis AG
    Inventors: Immaculada Margarit Y Ros, Guido Grandi, Chiara Zingaretti
  • PARASITE VACCINE
    Publication number: 20130064853
    Abstract: The present invention provides one or more antigens from the fourth stage (L4) larvae of non-blood feeding parasitic nematodes, for raising an immune responses in an animals, in particular bovines. The invention further provides methods of making immunogenic and/or vaccine compositions.
    Type: Application
    Filed: December 20, 2010
    Publication date: March 14, 2013
    Inventors: William David Smith, George Fredrick James Newlands, Stuart Smith, Aileen Halliday
  • Polypeptide specifically binding to vascular endothelial growth factor, fusion protein including polypeptide, and methods therefor
    Patent number: 8388976
    Abstract: A polypeptide inhibiting binding between a vascular endothelial growth factor and a vascular endothelial growth factor receptor, a fusion protein including the same, and a method of preparing the fusion protein are disclosed.
    Type: Grant
    Filed: August 17, 2012
    Date of Patent: March 5, 2013
    Assignee: Samsung Electronics Co., Ltd.
    Inventors: A-yeon Cho, Min-kyung Kim, Brian Hosung Min, Jong-sang Ryu
  • Protein fragments of virB10 and sero-detection of
    Patent number: 8389678
    Abstract: Disclosed are cloning and expression of a plurality of protein fragments of virB10, a Type IV Secretion System (TIVSS) in Anaplasma phagocytophilum. Such recombinant protein fragments are useful in the ELISA detection of anaplasma pathogen. The use of same as kits for ELISA is also disclosed.
    Type: Grant
    Filed: March 13, 2012
    Date of Patent: March 5, 2013
    Assignee: Medical Diagnostic Laboratories, LLC
    Inventors: John G. Hoey, Denise P. Dimitrov, Lisa B. Huang, Martin E. Adelson, Eli Mordechai
  • Yeast-based therapeutic for chronic hepatitis C infection
    Patent number: 8388980
    Abstract: Disclosed are compositions, including vaccines, and methods for vaccinating an animal against hepatitis C virus (HCV) and for treating or preventing hepatitis C viral infection in an animal. The invention includes a variety of novel HCV fusion proteins that can be used directly as a vaccine or in conjunction with a yeast-based vaccine vehicle to elicit an immune response against HCV in an animal. The invention also includes the use of the HCV fusion gene and protein described herein in any diagnostic or therapeutic protocol for the detection and/or treatment or prevention of HCV infection.
    Type: Grant
    Filed: December 4, 2009
    Date of Patent: March 5, 2013
    Assignee: GlobeImmune, Inc.
    Inventors: Richard C. Duke, Alex Franzusoff, Aurelia Haller, Thomas H. King
  • NOVEL IMMUNOMODULATORY PEPTIDE
    Publication number: 20130052213
    Abstract: The present invention relates a cleaved mammalian beta defensin with immunomodulatory properties. The cleaved or truncated peptides may be as potent as the full length mammalian beta defensins and may be used in the treatment of immunological and autoimmune disorders including but not limited to inflammatory bowel disease, and rheumatoid arthritis.
    Type: Application
    Filed: August 17, 2012
    Publication date: February 28, 2013
    Applicant: Novozymes A/S
    Inventors: Tanja Maria Rosenkilde Kjaer, Birgitte Andersen
  • TARGETED HETEROLOGOUS ANTIGEN PRESENTATION ON CALICIVIRUS VIRUS-LIKE PARTICLES
    Publication number: 20130052216
    Abstract: The present invention provides particle-forming chimeric proteins comprising a Calicivirus capsid protein and one or more heterologous antigen sequences. In particular, the present invention discloses engineered Calicivirus capsid protein sequences containing heterologous epitopes fused at internal locations such that the modified capsid proteins retain the ability to form virus-like particles when expressed in host cells. Virus-like particles comprising the chimeric proteins and vaccine formulations are also described.
    Type: Application
    Filed: January 21, 2011
    Publication date: February 28, 2013
    Applicant: LIGOCYTE PHARMACEUTICALS, INC.
    Inventors: Bryan Steadman, Ross Taylor
  • NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING GASTROINTESTINAL AND GASTRIC CANCER
    Publication number: 20130045191
    Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 95 novel peptide sequences and their variants derived from HLA class I molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
    Type: Application
    Filed: March 15, 2011
    Publication date: February 21, 2013
    Applicant: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Toni Weinschenk, Jens Fritsche, Steffen Walter, Peter Lewandrowski, Harpreet Singh
  • IMMUNOGENIC COMPOSITION
    Publication number: 20130045231
    Abstract: Compositions for the treatment or prevention of Neisserial infection and methods for their use and manufacture are provided herein.
    Type: Application
    Filed: March 10, 2011
    Publication date: February 21, 2013
    Inventors: Jan Poolman, Cindy Castado, Vincent Weynants, Nathalie Isabelle Devos
  • Recombinant merozoite surface proteins 4 and 5 and their use
    Patent number: 8378087
    Abstract: Accordingly, the invention provides constructs in which the nucleic acids encoding Plasmodium falciparum MSP4 and MSP5, and the resulting polypeptides, have been modified. More particularly, this invention provides constructs encoding recombinant MSP4 and MSP5 polypeptides, which are expressed as soluble, secreted polypeptides in a baculovirus-insect cell expression system. It was surprisingly found that the recombinant polypeptides contain an EGF-like domain at the C-terminus that is properly folded in the polypeptide.
    Type: Grant
    Filed: March 18, 2011
    Date of Patent: February 19, 2013
    Assignee: Institut Pasteur
    Inventors: Shirley Longacre, Hannah Polson, Ronald Perraut, Faridabano Nato
  • Fusion molecule based on novel TAA variant
    Patent number: 8378084
    Abstract: This invention provides novel carbonic anhydrase (CAIX) nucleic acid and peptide sequences, as well as related methods and compositions, including anti-cancer immunogenic agent(s) (e.g. vaccines and chimeric molecules) that elicit an immune response specifically directed against cancer cells expressing a CAIX antigenic marker. The novel CAIX variant and related compositions are useful in a wide variety of treatment modalities including, but not limited to protein vaccination, DNA vaccination, and adoptive immunotherapy.
    Type: Grant
    Filed: December 21, 2007
    Date of Patent: February 19, 2013
    Assignee: The Regents of the University of California
    Inventors: Zhenhua Li, Arie S. Belldegrun
  • RECOMBINANT MULTIMERIC INFLUENZA PROTEINS
    Publication number: 20130034578
    Abstract: The invention relates to immunogenic compositions comprising recombinant multimeric influenza proteins or parts thereof fused to a streptavidin affinity tag, preferably recombinant trimeric influenza virus hemagglutinin and/or recombinant tetrameric influenza virus neuraminidase, or vectors comprising nucleic acid sequences encoding such influenza proteins. The inventions further relate to methods for the preparation of such immunogenic compositions and uses thereof and methods for eliciting an immune response in an individual.
    Type: Application
    Filed: April 8, 2011
    Publication date: February 7, 2013
    Inventors: Petrus Josephus Marie Rottier, Berend Jan Bosch, Cornelis Alexander Maria De Haan
  • RECOMBINANT PROTEINS FOR USE IN VACCINE, ANTIBODIES AGAINST SAID PROTEINS, AND DIAGNOSTIC AND THERAPEUTIC METHODS INCLUDING THE SAME
    Publication number: 20130034560
    Abstract: The present invention relates to proteins and/or fragments and derivatives thereof and their use as vaccines and in biotechnological methods. The vaccines particularly include immunogenic proteins in Treponema spp. isolated from digital dermatitis in cattle. The present invention further relates to antibodies raised against said proteins or fragments thereof, and the use of said proteins in diagnostic methods in which antibodies are detected as a sign of digital dermatitis in cattle.
    Type: Application
    Filed: January 28, 2011
    Publication date: February 7, 2013
    Inventors: Anna Rosander, Märit Pringle
  • Methods to increase antigenicity of membrane bound polypeptides produced in plants
    Publication number: 20130028928
    Abstract: Increased antigenicity of a membrane bound polypeptide produced from plants is provided by reducing fat content of the plant, plant part, or plant tissue producing the polypeptide. Methods and means of producing such plant material are provided. Methods to produce a protective immune response in animals are provided by administering to the animal the plant, plant part of plant tissue which has reduced fat content and which comprises the polypeptide or by administering to the animal an extracted polypeptide produced from such a plant.
    Type: Application
    Filed: July 26, 2012
    Publication date: January 31, 2013
    Applicant: APPLIED BIOTECHNOLOGY INSTITUTE
    Inventors: John Howard, Celine Hayden
  • Process for preparing variant of surface protective antigen in
    Patent number: 8361749
    Abstract: A variant of Erysipelothrix rhusiopathiae surface protective antigen SpaA protein or of a shortened form of SpaA (?SpaA) in which a portion of SpaA protein is deleted for protection from Erysipelothrix rhusiopathiae infection and a process for preparing the same are provided. Introduction of amino acid substitution at a specific site in the amino acid sequence of SpaA or ?SpaA protein provides a variant of SpaA or ?SpaA protein which is immunogenic and is expressed in E. coli as inclusion bodies. The variant of SpaA or ?SpaA protein of the present invention may easily be recovered and purified since it is expressed in E. coli as inclusion bodies.
    Type: Grant
    Filed: November 18, 2010
    Date of Patent: January 29, 2013
    Assignee: Juridical Foundation The Chemo-Sero-Therapeutic Research Institute
    Inventors: Toshihiro Ushijima, Masashi Sakaguchi, Eiji Tokunaga
  • VACCINE FOR CHIKUNGUNYA VIRUS INFECTION
    Publication number: 20130022631
    Abstract: The present invention relates to vaccine formulation capable of eliciting protective immune response against Chikun-gunya virus infection in humans and other mammalian hosts. The immunogenic formulation comprises purified inactivated Chikun-gunya virus in a stable formulation. Methods of propagation and purification of the virus are discussed. The inactivated virus formulation is non-infectious, immunogenic and elicits protective immune response in mammalian host. The immunogenic composition is formulated for in vivo administration to humans. The invention also discusses the strategy of developing a subunit vaccine using the recombinant viral proteins as antigens for immunization. The recombinant virus antigens that are potentially immunogenic can be used in diagnosing for the presence of the virus.
    Type: Application
    Filed: August 31, 2007
    Publication date: January 24, 2013
    Inventors: Krishna Murthy Ella, Kandaswamy Sumathy, Jaya Sheela Pydigummala, Nagendra R. Hedge
  • PREPARATION OF PROTECTIVE ANTIGEN
    Publication number: 20130017573
    Abstract: A polynucleotide sequence is provided comprising a nucleic acid sequence encoding recombinant Protective Antigen (rPA). Also provided are expression vectors and host cells comprising the polynucleotide sequence of the invention, and methods for producing rPA.
    Type: Application
    Filed: June 27, 2012
    Publication date: January 17, 2013
    Inventors: John Brehm, Ian McEntee, Philip Vincent, Nigel Allison, Rossalyn Brehm, George Jack, Michael Herbert, Barbara T. Solow, Juan Arroyo, Randall K. Lapcevich
  • CODON MODIFIED POLYNUCLEOTIDE SEQUENCES FOR ENHANCED EXPRESSION IN A HOST SYSTEM
    Publication number: 20130017572
    Abstract: Synthetic DNA molecules encoding various HPV proteins are provided. The codons of the synthetic molecules are designed so as to use the codons that preferentially increase expression of the polypeptide in the host cell, which in preferred embodiments is a human cell. The codons are modified in order to minimize, decrease or eliminate cellular destruction of the polypeptide construct.
    Type: Application
    Filed: April 30, 2010
    Publication date: January 17, 2013
    Inventors: Peter S. Lu, Johannes Schweizer, Chamorro Somoza Diaz-Sarmiento
  • Recombinant merozoite surface proteins 4 and 5 and their use
    Patent number: 8350019
    Abstract: Accordingly, the invention provides constructs in which the nucleic acids encoding Plasmodium falciparum MSP4 and MSP5, and the resulting polypeptides, have been modified. More particularly, this invention provides constructs encoding recombinant MSP4 and MSP5 polypeptides, which are expressed as soluble, secreted polypeptides in a baculovirus-insect cell expression system. It was surprisingly found that the recombinant polypeptides contain an EGF-like domain at the C-terminus that is properly folded in the polypeptide.
    Type: Grant
    Filed: November 23, 2006
    Date of Patent: January 8, 2013
    Assignees: Institut Pasteur, Centre National de la Recherche Scientifique
    Inventors: Shirley Longacre, Hannah Polson, Ronald Perraut, Farida Nato
  • VACCINE
    Publication number: 20130004510
    Abstract: Compositions and methods for the treatment or prevention of Gram-negative bacterial strain infection are provided herein. Methods for the manufacture of said compositions are also provided herein.
    Type: Application
    Filed: March 11, 2011
    Publication date: January 3, 2013
    Inventors: Jan Poolman, Michiel Stork, Johannes Petrus Maria Tommassen, Nathalie Isabelle Devos, Vincent Weynants
  • BOTULINUM NEUROTOXIN ANTIGENIC COMPOSITIONS AND METHODS
    Publication number: 20120328642
    Abstract: Methods and compositions pertaining to botulinum neurotoxin (BoNT) light chain epitopes are provided. In particular, the methods and compositions relate to the use of real and mimetic BoNT light chain epitopes for generating an immune response in a subject, and for immunization against BoNT toxicity. Methods and compositions for detecting, isolating, and purifying BoNT epitopes and anti-BoNT antibodies are also provided.
    Type: Application
    Filed: February 18, 2011
    Publication date: December 27, 2012
    Inventor: Alexey Gennadievich Zdanovsky
  • Compositions and methods for diagnosing patients with acute atherosclerotic syndrome
    Patent number: 8338117
    Abstract: The present invention is in the field of autoimmunity. More specifically, the present invention relates to the detection of autoantibodies to domain 4 of beta 2-glycoprotein I (?2-GPI) as an indicator for atherosclerosis.
    Type: Grant
    Filed: June 4, 2010
    Date of Patent: December 25, 2012
    Assignee: Inova Diagnostics, Inc.
    Inventors: G. Michael Iverson, Walter L. Binder, Gary L. Norman
  • GROUP A STREPTOCOCCUS MULTIVALENT VACCINE
    Publication number: 20120321657
    Abstract: Immunogenic compositions are provided herein that are useful for inducing an immune response specific against group A streptococcus (GAS). Immunogenic compositions provided herein are multivalent and comprise a plurality of immunogenic peptides or fusion polypeptides comprising the immunogenic peptides that induce an immune response against GAS. The immunogenic compositions provided herein induce an immune response against the GAS serotypes represented by an immunogenic peptide (derived from an M protein or Spa protein) comprised within the immunogenic composition and also induce an immune response against serotypes that are unrepresented by any immunogenic peptide included in the immunogenic composition. Methods for using the compositions for inducing an immune response against GAS and for treating or reducing the likelihood of occurrence of a GAS infection are also provided.
    Type: Application
    Filed: June 15, 2012
    Publication date: December 20, 2012
    Applicant: UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION
    Inventor: James B. Dale
  • LENTIVIRUS VACCINE BASED ON THE RECOMBINANT VIRAL VACCINE AGAINST YELLOW FEVER
    Publication number: 20120321655
    Abstract: The present invention relates to an attenuated, recombinant viral vaccine against yellow fever which expresses heterologous sequences of a lentivirus and is used as an immunisation agent to induce an immune response to lentivirus.
    Type: Application
    Filed: December 22, 2010
    Publication date: December 20, 2012
    Inventors: Myrna Cristina Bonaldo, Ricardo Galler, David Ian Watkins, Jonah Bradley Sacha
  • EXPRESSION MEDIA FOR PROTEINS IN YEAST SYSTEM
    Publication number: 20120315671
    Abstract: The subject invention provides advantageous new media formulations, methods for their production, methods for cultivating cells using the media as well as compositions thereof and their use for enhanced expression of recombinant proteins. In certain embodiments, the subject invention provides media for use in producing recombinant proteins in yeast systems, such as Pichia pastoris.
    Type: Application
    Filed: June 11, 2012
    Publication date: December 13, 2012
    Applicant: UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION
    Inventors: NITIN JAIN, Seth Andrew Albright
  • Preparation of protective antigen
    Patent number: 8323927
    Abstract: A polynucleotide sequence is provided comprising a nucleic acid sequence encoding recombinant Protective Antigen (rPA). Also provided are expression vectors and host cells comprising the polynucleotide sequence of the invention, and methods for producing rPA.
    Type: Grant
    Filed: September 27, 2011
    Date of Patent: December 4, 2012
    Assignees: Health Protection Agency, Dynport Vaccine Company LLC
    Inventors: John Brehra, Ian McEntee, Philip Vincent, Nigel Allison, Rossalyn Brehm, George Jack, Michael Herbert, Barbara T. Solow, Juan Arroyo, Randall K. Lapcevich
  • Plasmodium vivax Hybrid Circumsporozoite Protein and Vaccine
    Publication number: 20120301497
    Abstract: Described in this application is a synthetic P. vivax circumsporozoite protein useful as a diagnostic reagent, for antibody production, and as a vaccine protective against infection with any strain of P. vivax.
    Type: Application
    Filed: August 3, 2012
    Publication date: November 29, 2012
    Inventors: Anjali Yadava, Christian F. Ockenhouse
  • METHOD
    Publication number: 20120297507
    Abstract: A method for producing leafy biomass from undifferentiated plant cells, the method comprising providing undifferentiated plant cells, contacting them with an agent that promotes differentiation of the cells into leafy tissue and growing the cells in a temporary liquid immersion culture system. This method of the invention may be used to produce polypeptides, and natural medicinal products, and can be used to capture carbon dioxide. A method of producing a polypeptide in plant cells in vitro comprising: providing undifferentiated plant cells containing chloroplasts that carry a transgenic nucleic acid molecule encoding the polypeptide, wherein the plant cells display homoplastomy; and propagating the cells according to the above method to produce leafy biomass containing the polypeptide.
    Type: Application
    Filed: August 12, 2010
    Publication date: November 22, 2012
    Applicant: Imperial Innovations Limited
    Inventors: Franck Michoux, Peter Nixon, James Gerard McCarthy
  • CONSENSUS SEQUENCE FOR INFLUENZA A VIRUS
    Publication number: 20120294879
    Abstract: Pandemic A(H1N1) continues its global spread, and vaccine production is a serious problem. Protection by current vaccines is limited by the mutational differences that rapidly accumulate in the circulating strains, especially in the virus surface proteins. New vaccine strategies are focusing at conserved regions of the viral internal proteins to produce T cell epitope-based vaccines. T cell responses have been shown to reduce morbidity and promote recovery in mouse models of influenza challenge. We previously reported 54 highly conserved sequences of NP, M1 and the polymerases of all human H1N1, H3N2, H1N2, and H5N1, and avian subtypes over the past 30 years. Sixty-three T cell epitopes elicited responses in HLA transgenic mice (A2, A24, B7, DR2, DR3 and DR4). These epitopes were compared to the 2007-2009 human H1N1 sequences to identify conserved and variant residues.
    Type: Application
    Filed: October 13, 2010
    Publication date: November 22, 2012
    Applicants: NATIONAL UNIVERSITY OF SINGAPORE, THE JOHNS HOPKINS UNIVERSITY
    Inventors: J. Thomas August, Paul ThiamJoo Tan, Tin Wee Tan, Mohammad Asif Khan
  • Expression system
    Patent number: 8313928
    Abstract: An immunogenic reagent which produces an immune response which is protective against Bacillus anthracis, said reagent comprising one or more polypeptides which together represent up to three domains of the full length Protective Antigen (PA) of B. anthracis or variants of these, and at least one of said domains comprises domain 1 or domain 4 of PA or a variant thereof. The polypeptides of the immunogenic reagent as well as full length PA are produced by expression from E. coli. High yields of polypeptide are obtained using this method. Cells, vectors and nucleic acids used in the method are also described and claimed.
    Type: Grant
    Filed: March 26, 2007
    Date of Patent: November 20, 2012
    Assignee: The Secretary of State for Defense
    Inventors: Ethel Diane Williamson, Julie Miller, Nicola Jane Walker, Leslie William James Baillie, Paula Thomson Holden, Helen Claire Flick-Smith, Helen Lisa Bullifent, Richard William Titball, Andrew William Topping
  • TYPE IV SECRETION SYSTEM PROTEINS IN SERO-DETECTION OF ANAPLASMA PHAGOCYTOPHILUM
    Publication number: 20120288882
    Abstract: Disclosed are two (2) proteins in the Type IV Secretion System (TIVSS) in Anaplasma phagocytophilum (namely, virB 10 and virB 11) useful in the ELISA detection of Anaplasma pathogen. The recombinant expression of virB 10 and virB 11 and their use as kits for ELISA are also disclosed.
    Type: Application
    Filed: July 30, 2012
    Publication date: November 15, 2012
    Applicant: MEDICAL DIAGNOSTIC LABORATORIES, LLC
    Inventors: John G. Hoey, Denise P. Dimitrov, Lisa P. Huang, Martin E. Adelson, Eli Mordechai
  • DNA SEQUENCE AND PREPARATION OF GRASS POLLEN ALLERGEN PHL P4 BY RECOMBINANT METHODS
    Publication number: 20120288526
    Abstract: The present invention relates to the provision of the genetic sequence of the major grass pollen allergen Phl p 4. The invention covers fragments, new combinations of partial sequences and point mutants having a hypoallergenic action. The recombinant DNA molecules and the derived polypeptides, fragments, new combinations of partial sequences and variants can be utilised for the therapy of pollen-allergic diseases. The proteins prepared by recombinant methods can be employed for the in vitro and in vivo diagnosis of pollen allergies.
    Type: Application
    Filed: February 24, 2011
    Publication date: November 15, 2012
    Applicant: Merck Patent GmbH
    Inventors: HELMUT FIEBIG, ANDREAS NANDY, ROLAND SUCK, OLIVER CROMWELL, ARND PETERSEN, WOLF-MEINHARD BECKER
  • Intergenic regions as insertion sites in the genome of modified vaccinia virus ankara (MVA)
    Patent number: 8309326
    Abstract: The present invention relates to novel insertion sites useful for the integration of exogenous sequences into the Modified Vaccinia Ankara (MVA) virus genome. The present invention further provides plasmid vectors to insert exogenous DNA into the genome of MVA. Furthermore, the present invention provides recombinant MVA comprising an exogenous DNA sequence inserted into the new insertion site as medicine or vaccine.
    Type: Grant
    Filed: April 15, 2011
    Date of Patent: November 13, 2012
    Assignee: Bavarian Nordic A/S
    Inventors: Paul Howley, Sonja Leyrer
  • STAPHYLOCOCCAL ANTIGENS
    Publication number: 20120282289
    Abstract: The present invention provides novel sequences encoding Staphylococcus pseudintermedius proteins/nucleic acids potentially useful in the treatment and/or prevention of canine disorders. In particular, the various protein and/or nucleic acid sequences described herein may find application as vaccines for use in treating and/or preventing a variety of canine diseases and/or conditions caused or contributed to by Staphylococcus pseudintermedius.
    Type: Application
    Filed: April 13, 2012
    Publication date: November 8, 2012
    Inventors: JEANETTE BANNOEHR, Ross J. FITZGERALD, NOURI L. BEN ZAKOUR
  • Mycobacterial Vaccines
    Publication number: 20120282290
    Abstract: There is provided a fusion protein or a polynucleotide sequence encoding said fusion protein that comprises first and second domains, wherein the first domain of the fusion protein comprises an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO: 1, or a fragment thereof comprising at least 20 consecutive amino acids thereof; and wherein the second domain of the fusion protein comprises a mycobacterial antigen or an antigenic fragment thereof. Also provided are corresponding therapeutic uses thereof for the protection of primates against mycobacterial infections.
    Type: Application
    Filed: October 15, 2010
    Publication date: November 8, 2012
    Applicants: IMAXIO SA, ISIS INNOVATION LIMITED
    Inventors: Alexandra Jane Spencer, Matthew Guy Cottingham, Adrian Vivian Sinton Hill, Fergal Hill
  • Nucleic acid and amino acid sequences relating to for diagnostics and therapeutics
    Patent number: 8298788
    Abstract: The invention provides isolated polypeptide and nucleic acid sequences derived from Streptococcus pneumoniae that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting from bacterial infection.
    Type: Grant
    Filed: April 27, 2007
    Date of Patent: October 30, 2012
    Assignee: Sanofi Pasteur Limited
    Inventors: Lynn Doucette-Stamm, David Bush, Qiandong Zeng, Timothy Opperman, Chad Eric Houseweart
  • EXPRESSION CASSETTES ENDCODING HIV-1 SOUTH AFRICAN SUBTYPE C MODIFIED PROTEINS
    Publication number: 20120269851
    Abstract: The present invention relates to polynucleotides encoding immunogenic HIV polypeptides. Uses of the polypeptides in applications including immunization, generation of packaging cell lines, and production of HIV polypeptides are also described. Polynucleotides encoding antigenic HIV polypeptides are described, as are uses of these polynucleotides and polypeptide products therefrom, including formulations of immunogenic compositions and uses thereof.
    Type: Application
    Filed: February 17, 2012
    Publication date: October 25, 2012
    Applicants: University of Stellenbosch, NOVARTIS VACCINES & DIAGNOSTICS, INC.
    Inventors: Jan zur Megede, Susan Barnett, Ying Lian, Susan Engelbrecht, Estrelita Janse van Rensburg, Thomas J. Scriba
  • Nucleic acid and amino acid sequences relating to for diagnostics and therapeutics
    Patent number: 8293884
    Abstract: The invention provides isolated polypeptide and nucleic acid sequences derived from Streptococcus pneumoniae that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting from bacterial infection.
    Type: Grant
    Filed: April 27, 2007
    Date of Patent: October 23, 2012
    Assignee: Sanofi Pasteur Limited/Sanofi Pasteur Limitée
    Inventors: Lynn Doucette-Stamm, David Bush, Qiandong Zeng, Timothy Opperman, Chad Eric Houseweart
  • VARIANTS OF THE MAJOR ALLERGEN PHL P 1 FROM TIMOTHY GRASS
    Publication number: 20120263741
    Abstract: The invention relates to pharmaceutically important variants of the major allergen Phl p 1 from timothy grass, characterised in that a preparation, hitherto not possible, of monomeric molecules which are soluble and stable in physiological media can be carried out with the aid of prokaryotic expression systems and subsequent purification thereof.
    Type: Application
    Filed: March 22, 2010
    Publication date: October 18, 2012
    Inventors: Roland SUCK, Helmut Fiebig, Oliver Cromwell
  • Nucleic acid and amino acid sequences relating to for diagnostics and therapeutics
    Patent number: 8288519
    Abstract: The invention provides isolated polypeptide and nucleic acid sequences derived from Streptococcus pneumoniae that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting from bacterial infection.
    Type: Grant
    Filed: April 27, 2007
    Date of Patent: October 16, 2012
    Assignee: Sanofi Pasteur Limited
    Inventors: Lynn Doucette-Stamm, David Bush, Qiandong Zeng, Timothy Opperman, Chad Eric Houseweart
  • Intergenic regions as insertion sites in the genome of modified vaccinia virus Ankara (MVA)
    Patent number: 8288125
    Abstract: The present invention relates to novel insertion sites useful for the integration of exogenous sequences into the Modified Vaccinia Ankara (MVA) virus genome. The present invention further provides plasmid vectors to insert exogenous DNA into the genome of MVA. Furthermore, the present invention provides recombinant MVA comprising an exogenous DNA sequence inserted into the new insertion site as medicine or vaccine.
    Type: Grant
    Filed: April 15, 2011
    Date of Patent: October 16, 2012
    Assignee: Bavarian Nordic A/S
    Inventors: Paul Howley, Sonja Leyrer
  • Construct
    Publication number: 20120258133
    Abstract: The present invention provides a construct which, when expressed in a host cell, is capable of producing empty virus capsids, the construct comprising: (i) a nucleotide sequence encoding a capsid precursor protein; (ii) a nucleotide sequence encoding a protease capable of cleaving the capsid precursor protein; and (iii) a control element which controls the expression of the protease such that, when the construct is present in the host cell, the control element causes the protease to be expressed at a level sufficient to cleave the capsid precursor protein, but not sufficient to induce significant toxicity in the host cell. The invention also provides a vector and a host cell comprising such a construct and their use to generate empty virus capsids.
    Type: Application
    Filed: September 24, 2010
    Publication date: October 11, 2012
    Applicant: Institute for Animal Health
    Inventors: Bryan Charleston, Ian Jones
  • Retroviral Vector Particles and Methods for their Generation and Use
    Publication number: 20120258494
    Abstract: The present invention relates to methods of host cell transduction utilising ecotropic retroviral vector particles. The retroviral vector particle may comprise an envelope of Friend murine leukaemia virus, in particular the envelope encoded by molecular clone PVC-211 and the host cell may be engineered to recombinantly express the Reel receptor. The retroviral vector particles and methods of the invention can be used to introduce expressible polynucleotide sequences of interest into host cells with high efficiency. This results in protein production methods with higher yield (mg/L) and a reduction in manufacturing costs that could be used in a range of applications including for example, the production of therapeutic proteins, vaccines and antibodies.
    Type: Application
    Filed: November 22, 2010
    Publication date: October 11, 2012
    Applicant: 4-Anitbody AG
    Inventor: Jörn Stitz
  • ANTIBODIES AGAINST HUMAN CCN1 AND USES THEREOF
    Publication number: 20120258112
    Abstract: Disclosed herein are methods for the recombinant expression of mammalian cell membrane-bound human CCN1 or a CCN1 domain thereof in mammalian cells, comprising transforming a mammalian host cell with a vector encoding CCN1 or a CCN1 domain thereof C-terminally fused to a mammalian cell transmembrane domain (CCN1 fusion protein), expressing said CCN1 or CCN1 domain fusion protein in said host cell, and recovering said membrane bound CCN1 or said CCN1 domain thereof. Disclosed herein is the use of such membrane bound CCN1 and domain for the generation of corresponding antibodies. Antibodies against human CCN1 are useful for the treatment of diseases.
    Type: Application
    Filed: April 13, 2012
    Publication date: October 11, 2012
    Inventors: Hendrik Knoetgen, Hans-Willi Krell, Sandra Miller, Jens Niewoehner, Dirk Ponsel, Engin Toksoez
  • Method for detecting syphilis using synthetic antigens
    Patent number: RE43914
    Abstract: An antigen composition and method for the detection of antibodies to Treponema pallidum and the diagnosis of syphilis are described. The antigen composition contains synthetic cardiolipin and synthetic lecithin. The antigen composition may additionally contain cholesterol and an alcohol. The antigen composition is useful as an immunoreagent in immunoassays for the detection of antibodies associated with T. pallidum infection. The methods are sensitive and specific for T. pallidum infection.
    Type: Grant
    Filed: June 8, 2000
    Date of Patent: January 8, 2013
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention
    Inventor: Arnold R. Castro